#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2021

#### **Stoke Therapeutics, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or other jurisdiction of incorporation or organization)

001-38938 (Commission File Number) 47-114582 (I.R.S. Employer Identification No.)

45 Wiggins Ave Bedford, Massachusetts (Address of principal executive offices)

01730 (Zip Code)

Registrant's telephone number, including area code: (781) 430-8200

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Dere-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, \$0.0001 par value per share	STOK	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

#### Item 7.01 Regulation FD.

On February 5, 2021, Stoke Therapeutics, Inc. (the "Company") updated its corporate presentation with information about the Company, which it intends to use as part of investor presentations. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished with this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

#### Item 8.01 Other Events.

Description

On February 5, 2021, the Company announced that in January 2021 it initiated enrollment and dosing in the Company's Swallowtail Open Label Extension (OLE) study for STK-001.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number

99.1 Presentation, dated as of February 2021.

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STOKE THERAPEUTICS, INC.

Date: February 5, 2021

By: /s/ Stephen J. Tulipano Stephen J. Tulipano Chief Financial Officer

# Stoke Therapeutics

. . . . . . . . . . . . . . . .

February 2021



# Disclaimer

This presentation has been prepared by Stoke Therapeutics, Inc. ("Stoke" or "our") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Stoke or any officer, director, employee, agent or advisor of Stoke. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Information provided in this presentation speaks only as of the date hereof. Stoke assumes no obligation to publicly update any information or forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, subsequent events, or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the ability of our TANGO platform to design medicines to increase protein production and the expected benefits thereof; the ability of STK-001 to treat the underlying causes of Dravet syndrome: the preclinical data and study results regarding OPA1: our preliminary cash, cash equivalents and restricted cash and shares outstanding as of December 31, 2020: our future operating results, financial position and liquidity; the direct and indirect impact of COVID-19 on our business, financial condition and operations, including on our expenses, supply chain, strategic partners, research and development costs, clinical trials and employees; our expectation about timing and execution of anticipated milestones, responses to regulatory authorities, expected nomination of future product candidates and timing thereof. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "potential," "possible," "will," "would," and other words and terms of similar meaning. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such statements, including: our ability to develop, obtain regulatory approval for and commercialize STK-001, OPA1 and future product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets; environmental risks; risks relating to the use of social media for our business; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements.

By attending or receiving this presentation you acknowledge that you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made; you will be solely responsible for your own assessment of the market and our market position; and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of Stoke.




# STOKE THERAPEUTICS Boldly Restoring Genetic Health

Addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines.

# A Differentiated Platform for the Discovery and Development of Novel RNA-based Medicines





© Copyright 2021 Stoke Therapeutics 4


ST € KE

Targeted Augmentation of Nuclear Gene Output

## Our compounds aim to restore protein levels by increasing protein production from the functional copy of a gene and:

- Selectively boost expression only in tissues where the protein is normally expressed
- Offer one drug for diseases caused by many different mutations
- Apply to genes of diverse size: can be used to address small or large gene targets

TANGO ASOs Demonstrate Dose-Dependent Increases in Protein Expression Across Targets of Diverse Size, Type and Function



6


ST∳KE

communications Lim et al., Nat Comm, 2020

NT: non-targeting ASO control, all experiments n = 3, in vitro

# Dravet Syndrome: A Severe, Progressive Genetic Epilepsy

ST∳KE



<sup>1</sup> Sudden Unexpected Death in Epilepsy

Sources: 2018 Health Advances Report; Djémié et al., Molecular Genetics & Genomic Medicine, 2016; Lagae et al., Developmental Medicine & Child Neurology, 2017; Nabbout et al., Orphanet Journal of Rare Diseases, 2013




# No Approved Disease-Modifying Therapies for Dravet Syndrome


#### Non-Seizure Comorbidities of Dravet Syndrome Are Not Addressed by Current Therapies


- Intellectual disability
- Developmental delays
- Movement and balance issues
- Language and speech disturbances
- Growth defects
- Sleep abnormalities
- Chronic infections
- Disruptions of the autonomic nervous system
- Mood disorders

© Copyright 2021 Stoke Therapeutics 8

ST€→KE







Placebo

STK-001

14 WEEKS

p<0.0001

Sources: Han et al., Science Trans Med, 2020

SCN1a+/

50

0

Placebo


STK-001

7 WEEKS

p<0.0001

# STK-001 Significantly Reduces Premature Mortality in DS Mice After a Single Dose

Significant improvements in survival after STK-001 administration at postnatal day 2




Translationa Medicine

Sources: Han et al., Science Trans Med, 2020

© Copyright 2021 Stoke Therapeutics 12

# STK-001 Administration Reduces Seizure Frequency in DS Mice


•••••




Source: Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN1A reduces seizures and rescues parvalbumin positive interneuron firing frequency in a mouse model of Dravet syndrome (AES 2020)

© Copyright 2021 Stoke Therapeutics 13

# STK-001 Achieves Broad Distribution and Increases Nav1.1 Protein Expression in NHPs





NHP = Non-human primate Source (left graph): Stoke data Source (right graph) TANGO oligonucleotides for the treatment of Dravet Syndrome: Safety, biodistribution and pharmacology in the non-human primate (AES 2019)

Single and Multiple-Dose Toxicology Studies in NHPs Showed STK-001 Well-Tolerated

# Key safety findings from GLP studies\*

N h

Ν

re

N b

o observed adverse events at ighest dose tested	<ul> <li>✓</li> </ul>
o change in platelet counts or enal/hepatic function	<ul> <li>Image: A start of the start of</li></ul>
o adverse histopathology in rain, spinal cord, liver and kidney	

\*In non-GLP studies in NHPs, at levels above the NOAEL, hind limb paresis was observed; at extremely high dose levels, acute convulsions were observed.

© Copyright 2021 Stoke Therapeutics 1


STK-001 Has Potential to Address the Genetic Cause of Dravet Syndrome (DS) Single dose restores Nav1.1 to near<br/>normal levels for >3 months in DS miceImage: Comparison of the series of the

© Copyright 2021 Stoke Therapeutics 16

# Non-Seizure Comorbidities of DS are Progressive and Measurable

## ST∳KE

## Enrollment completed (n=36, 2-18 year-olds). Study ongoing.



\* VABS = Vineland Adaptive Behavior Scales
\* ABC score based on Communication, Daily Living, and Socialization domains and expressed relative to normative mean of 100
Source: Observational Study to Investigate Cognition and Quality of Life in Children and Adolescents with Dravet Syndrome: Baseline Analysis of the BUTTERFLY Study (AES 2020)

<sup>©</sup> Copyright 2021 Stoke Therapeutics 17

# Enrollment and Dosing in MONARCH Phase 1/2a Trial is Ongoing

Design	<ul> <li>Open-label evaluation of single and multiple ascending doses of STK-001 (up to 30mg)</li> <li>SAD: Currently enrolling</li> <li>MAD: Planned initiation 2H 2021</li> <li>Doses &gt;30mg remain on FDA partial clinical hold</li> </ul>	
Target Enrollment	~48 children and adolescents ages 2-18 years old with Dravet syndrome and confirmed <i>SCN1a</i> variant	
Primary Endpoint	Safety and tolerability of single and multiple ascending dose levels; characterize human pharmacokinetics (PK)	
Secondary Endpoint	Change in seizure frequency over 12-weeks, quality of life	<b>MONATCH</b>
Preliminary Data	Initial safety and PK data anticipated in 2021	
Open-Label Extension	Currently enrolling	Swallowtail A DRAVET SYNDROME EXTENSION STUDY

Source: Safety and Pharmacokinetics of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome: Single and Multiple Ascending Dose Design for the Open-Label Phase 1/2a MONARCH Study (AES 2020)

© Copyright 2021 Stoke Therapeutics 18

# Autosomal Dominant Optic Atrophy (ADOA): A Severe, Progressive Optic Nerve Disorder

-----



Sources: Yu-Wai-Man P et al. Ophthalmology, 2010; Yu-Wai-Man P, Chinnery PF. Ophthalmology, 2013; P. Amati-Bonneau P et al. The International Journal of Biochemistry & Cell Biology, 2009; Lenaers G, Hamel C, Delettre C, et al. Orphanet J Rare Dis, 2012; Chun BY and Rizzo JF III. Curr Opin Ophthalmol, 2016; Le Roux B, Lenaers G, Zanlonghi X et al. Orphanet J Rare Dis, 2019; "What is ADOA?" Autosomal Dominant Optic Atrophy Association. Accessed May 6, 2020, from <a href="https://www.adoaa.org/what-is-adoa">https://www.adoaa.org/what-is-adoa</a>;"

© Copyright 2021 Stoke Therapeutics 19

ST€→KE

# No Approved Disease-Modifying Therapies for ADOA

ST∳KE

#### **Healthy Vision**

#### **Simulation of Optic Neuropathy**



- Most common inherited optic nerve disorder
- · Leads to central field defects and reduced color vision in both eyes
- · Severity can vary; rate of vision loss difficult to predict
- Supportive services and low-vision aids are offered for patients





© Copyright 2021 Stoke Therapeutics 20


Sources: Yu-Wai-Man P et al. Ophthalmology, 2010; Yu-Wai-Man P, Chinnery PF. Ophthalmology, 2013; Lenaers G, Hamel C, Delettre C, et al. Orphanet J Rare Dis, 2012; Chun BY and Rizzo JF III. Curr Opin Ophthalmol, 2016 Image of child sourced from ICR, Ophthalmology Center Barcelona. Accessed Jan. 8, 2021 from https://icrcat.com/en/eye-conditions/leber-hereditary-optic-neuropathy/ Society Sweden. Image shown depicts Leber Hereditary Optic Neuropathy, which presents visual effects similar to ADOA.

# OPA1 is Critical for Normal Mitochondrial Function and Cellular Metabolism

 Retinal ganglion cells have very high energy (ATP) requirements

- Impaired mitochondrial function leads to cell death
- OPA1 is critical for mitochondrial function and energy production

\* ROS = Reactive Oxygen Species




t

**Cell Death** 

© Copyright 2021 Stoke Therapeutics 21

# TANGO ASO Demonstrates Dose-Dependent OPA1 Protein Increases in Rabbit Retina




#### \*P<0.0005 by one-way ANOVA compared to PBS group

NMD = nonsense mediated decay

Source: TANGO oligonucleotides for the treatment of Dravet Syndrome: Safety, biodistribution and pharmacology in the non-human primate (AES 2019)

# TANGO ASO Partially Restores ATP and Protein Levels in Human OPA1 +/- Cells

. . . . . . . . . . . . . . .



Source: Stoke data

TANGO ASOs Have the Potential to Address the Genetic Cause of ADOA Dose-dependent increases in OPA1 protein expression in rabbit retina

Increases ATP and protein levels in human OPA1 +/- cells

Well tolerated for up to 29 days after intravitreal injection in rabbit

Lead optimization is underway to potentially identify a clinical candidate in 2021

## ST∳KE

 $\checkmark$ 

# Broad Therapeutic Potential for TANGO



Stoke identified a variety of non-productive alternative-splicing events that lead to mRNA degradation and limit protein production.

10K+

# **5%**

Genetic diseases are caused by mutations in a single gene Of these diseases are addressed by current therapeutic approaches

# ~1,200

Monogenic disease genes containing at least one NMD-inducing nonproductive event

# ~6,500

Additional unique genes found by Stoke that contained at least one NMD-inducing nonproductive event

© Copyright 2021 Stoke Therapeutics 25

**ST** KE

nature communications

Lim et al., Nat Comm, 2020

# 2021 Milestones STERE 1H2021 Initiate Swallowtail Open Label Extension (OLE) study of STK-001 2H2021 Initiate multiple ascending dose (MAD) study of STK-001 2H2021 Preliminary safety and PK data from Phase 1/2a MONARCH study of STK-001 2H2021 Initiate ADOA natural history data collection YE2021 Complete lead optimization for OPA1 compounds YE2021 Demonstrate *in vivo* proof of mechanism and safety for a third program

ST∳KE

# Current Financials Anticipated to Fund Operations into 2024



Cash, Cash Equivalents & Restricted Cash

as of 12/31/2020



#### **Common Shares Outstanding**

as of 12/31/2020

# We Are Stoke

United in our mission to address the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines.





Copyright Stoke Therapeutics, Inc. Not for publication or distribution

